CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 69 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,443,287 | +53593.7% | 1,183,022 | -4.0% | 0.00% | -50.0% |
| Q1 2024 | $2,688 | +30.8% | 1,232,800 | -7.0% | 0.00% | +33.3% |
| Q4 2023 | $2,055 | +71.2% | 1,325,700 | +42.5% | 0.00% | +50.0% |
| Q3 2023 | $1,200 | -37.9% | 930,100 | -17.1% | 0.00% | -33.3% |
| Q2 2023 | $1,931 | +50.4% | 1,122,400 | +32.0% | 0.00% | +50.0% |
| Q1 2023 | $1,284 | -40.1% | 850,300 | -36.6% | 0.00% | -33.3% |
| Q4 2022 | $2,145 | -99.9% | 1,340,774 | -25.7% | 0.00% | -25.0% |
| Q3 2022 | $2,618,000 | -1.6% | 1,805,600 | +24.2% | 0.00% | +33.3% |
| Q2 2022 | $2,661,000 | +11.2% | 1,454,261 | +62.3% | 0.00% | 0.0% |
| Q1 2022 | $2,392,000 | +9.3% | 895,900 | +77.2% | 0.00% | 0.0% |
| Q4 2021 | $2,189,000 | -51.9% | 505,500 | -43.5% | 0.00% | -50.0% |
| Q3 2021 | $4,554,000 | -29.9% | 894,600 | -12.8% | 0.01% | -25.0% |
| Q2 2021 | $6,496,000 | -42.1% | 1,026,200 | -29.4% | 0.01% | -42.9% |
| Q1 2021 | $11,228,000 | -17.0% | 1,452,568 | -29.6% | 0.01% | -6.7% |
| Q4 2020 | $13,522,000 | -11.8% | 2,064,500 | -10.4% | 0.02% | 0.0% |
| Q3 2020 | $15,326,000 | -21.7% | 2,304,600 | -2.0% | 0.02% | -11.8% |
| Q2 2020 | $19,581,000 | +15.6% | 2,350,671 | +6.5% | 0.02% | +6.2% |
| Q1 2020 | $16,935,000 | -1.2% | 2,208,000 | +7.0% | 0.02% | +23.1% |
| Q4 2019 | $17,146,000 | +51.6% | 2,063,271 | +34.7% | 0.01% | +30.0% |
| Q3 2019 | $11,308,000 | -28.4% | 1,532,300 | +8.9% | 0.01% | -28.6% |
| Q2 2019 | $15,787,000 | +13.8% | 1,407,000 | +9.0% | 0.01% | +7.7% |
| Q1 2019 | $13,874,000 | -30.3% | 1,290,600 | -2.1% | 0.01% | -40.9% |
| Q4 2018 | $19,899,000 | -29.3% | 1,317,800 | -13.3% | 0.02% | -24.1% |
| Q3 2018 | $28,129,000 | -52.8% | 1,520,500 | -35.9% | 0.03% | -12.1% |
| Q2 2018 | $59,613,000 | +118.0% | 2,372,700 | +146.8% | 0.03% | +10.0% |
| Q1 2018 | $27,346,000 | +81.1% | 961,200 | +34.4% | 0.03% | +76.5% |
| Q4 2017 | $15,096,000 | +54.5% | 715,100 | +32.9% | 0.02% | +41.7% |
| Q3 2017 | $9,774,000 | +53.5% | 537,900 | +30.9% | 0.01% | +50.0% |
| Q2 2017 | $6,369,000 | +57.1% | 410,900 | +75.0% | 0.01% | +33.3% |
| Q1 2017 | $4,055,000 | +304.7% | 234,800 | +157.5% | 0.01% | +200.0% |
| Q4 2016 | $1,002,000 | – | 91,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners IX LLC | 4,244,381 | $43,378,000 | 100.00% |
| VHCP Management II, LLC | 577,831 | $5,905,000 | 3.56% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 71,366 | $729,000 | 2.45% |
| Casdin Capital, LLC | 234,179 | $2,392,000 | 2.38% |
| BVF INC/IL | 606,138 | $6,192,000 | 1.32% |
| Opaleye Management Inc. | 160,000 | $1,634,000 | 1.09% |
| Redmile Group, LLC | 733,899 | $7,497,000 | 0.72% |
| VHCP Management, LLC | 64,200 | $656,000 | 0.68% |
| Montecito Bank & Trust | 146,544 | $1,497,000 | 0.63% |
| Cormorant Asset Management, LP | 371,636 | $3,796,000 | 0.54% |